A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
@EJC
doi.org/10.1016/j.ejca…
👉Stopped at IA due to futility
👉Comparable activity, safety manageable
🧐Not good, but both are options in 2nd line
ESMO - Eur. Oncology

Pertuzumab + Trastuzumab in Biliary Tract Cancer With ERBB2/3 Alterations
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
🔎 TAPUR phs 2
👉DC: 40%; ORR: 32%
👉PFS: 11; mOS 30 weeks
🧐Activity in pts w/ ERBB2/3 amplification, overexpression or mutations
ESMO - Eur. Oncology EASLnews ILCA Cholangiocarcinoma Foundation

First-Line Nivolumab & Relatlimab Plus CTx for GC or GEJ Adenocarcinoma
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
🔎Phs II RELATIVITY-060
🚫study, primary EP° not met
🤨lower CTx exposure in exp. arm with actually worse PFS/OS
ESMO - Eur. Oncology

Trastuzumab deruxtecan in HER2+ gastric cancer
Nature Medicine
doi.org/10.1038/s41591…
🔎exploratory biomarker analysis of DESTINY Gastric01
👉64% concordance btw HER2+ IHC & 🩸
👉MET, EGFR & FGFR2 GA: ORR⬇️
👉HER2 mutations: ORR⬆️
👉activity in Her2 low
ESMO - Eur. Oncology

Pemigatinib in previously treated solid tumors w/ activating FGFR1–FGFR3 GA
Nature Medicine
doi.org/10.1038/s41591…
🔎 FIGHT-207 basket
👉Fusions most responsive, but histology matters
👉C382R & in frameDel also responsive
👉BAP1: ORR⬆️
👉TP53: ORR⬇️
ESMO - Eur. Oncology ILCA EASLnews

Circadian tumor infiltration & function of CD8+ T cells dictate immunotherapy efficacy
Cell
doi.org/10.1016/j.cell…
👉Immune system stimulated once at the ‘‘wrong’’ time, may not be able to respond anymore to the same level
🤔Compelling data to support ICI infusion

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers
Annals of Oncology
doi.org/10.1016/j.esmo…
🔎13 trials meta-analysis, 1663 pts
⚡️early ToD groups had longer OS (HR 0.50) & PFS (HR
0.51)
🧐Strong evidence for early ToD ICI infusions

🌞Great sunny day in Toronto, just starting the Cholangiocarcinoma in PSC Symposium at University Health Network
🤩Looking forward to great talks and discussion on new strategies for prevention and treatment of cancer in PSC
ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation #livertwitter Gonzalo Sapisochin

Precision treatment in advanced HCC
Cancer Cell
doi.org/10.1016/j.ccel…
👏Excellent summary on precision medicine in HCC
👉all you need to know on molecular classification, biomarker, iTME & future directions...
ESMO - Eur. Oncology EASL Education ILCA #livertwitter

Safety & feasibility of CTx followed by liver transplantation for pts with definitely unresectable
CRC liver mets
eClinicalMedicine – The Lancet Discovery Science
doi.org/10.1016/j.ecli…
🔎 TransMet trail
🤔Interesting, highlights the challenges in this field
👉meticulous selection process is key
🧐LT outcome

🇪🇺Tumor-agnostic approval by EMA🇪🇺
Selpercatinib/ Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted
ESMO - Eur. Oncology

Multicentre phs II trial of cabozantinib in HCC after immune checkpoint inhibitors
Journal of Hepatology
doi.org/10.1016/j.jhep…
🧐Efficacy of Cabozantinib in 2nd line after ICI, but disappointing data in 3rd line
ESMO - Eur. Oncology Milca Malary EASL Education #livertwitter

Biliary tract cancers: 🇫🇷 national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
doi.org/10.1016/j.ejca…
👏comprehensive recommandations
ESMO - Eur. Oncology ILCA EASL Education

2nd line FOLFOX for biliary tract cancers pretreated with cisplatin/gemcitabine
ESMO Open
doi.org/10.1016/j.esmo…
🔎systematic review & meta-analysis of 6 trials
👉ORR 10%, DCR 50%, mPFS 3mo, mOS 6,5 mo
🤨Hmm, we need to do better...
ESMO - Eur. Oncology ILCA EASLnews #livertwitter

Primary Tumor Resection Before Systemic Therapy in CRC & Unresectable Metastases
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
🔎SYNCHRONOUS & CCRe-IV; 2011 - 2017, 393 pts
🚫No survival benefit for resection of the primary tumor at baseline
🧐24% in the PTR group no CTx
🤨overall

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Cancer Discovery
doi.org/10.1158/2159-8…
👉Surprisingly high efficacy of sotorasib, but not adagrasib to NRASG12C ( > KRAS G12C)
👉Rarely found, but interesting option...
ESMO - Eur. Oncology

Multicenter study on efficacy of immune checkpoint inhibitors in MSI non-CRC digestive cancers
European Journal of Cancer
doi.org/10.1016/j.ejca…
🔎RWD 🇫🇷🇧🇪, 133 pts
👉Clear superiority of ICI compared to CTx
🤨but ICI still not approved in many countries...
ESMO - Eur. Oncology

Tumor-Agnostic Precision Medicine from the AACR
GENIE Database: Clinical Implications
Clinical Cancer Research
doi.org/10.1158/1078-0…
👉Distribution of 5 tissue-agnostic targets with FDA approval among different cancer types : BRAFV600E, RET & NTRK fusions, TMBhigh & MSI
ESMO - Eur. Oncology